QQQ

DIA

SPY

TLT

GLD

BTC/USD

QQQ

DIA

SPY

TLT

GLD

BTC/USD

Range

6.73 - 7.96

Vol / Avg.

8.4M/985.7K

Div / Yield

-

52 Wk

6.73 - 24.3

Mkt Cap

529.2M

Payout Ratio

-

Open

7.89

P/E

-

EPS

-0.11

Shares

76.6M

Outstanding

76.6M

Total Float

68.7M

Analyst Ratings

Mid-Afternoon Market Update: Nasdaq Down 70 Points; Ocular Therapeutix Shares Drop

Benzinga - 1 day ago

Ocular Therapeutix shares are trading lower after the company announced topline results for its Phase 2 clinical trial of OTX-CSI for the treatment of dry eye disease did not meet the primary endpoint.

Benzinga - 1 day ago

Ocular Therapeutix Shares Resume Trade, Down 39%

Benzinga - 1 day ago

Ocular Therapeutix Shares Were Halted Ahead Of Recent News; Stock To Resume Trade At 8:30 a.m. EDT

Benzinga - 1 day ago

Ocular Therapeutix Announces Topline Results For Phase 2 Clinical Trial Of OTX-CSI For The Treatment Of Dry Eye Disease Did Not Meet Primary Endpoint

Benzinga - 1 day ago

Raymond James Maintains Strong Buy on Ocular Therapeutix, Raises Price Target to $29

Benzinga - 5 days ago

HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $18

Benzinga - Oct 12, 2021, 7:01AM

Why Are Ocular Therapeutix Shares Trading Higher Today?

Benzinga - Oct 11, 2021, 3:30PM

Ocular Therapeutix Announces FDA Approval Of Supplemental New Drug Application For DEXTENZA 0.4 mg For Intracanalicular Use For Treatment Of Ocular Itching Associated With Allergic Conjunctivitis

Benzinga - Oct 11, 2021, 12:31PM

Ocular Therapeutix Shares Move Higher; Traders Circulate Oct. 7 FDA Approval For Co's Dextenza

Benzinga - Oct 11, 2021, 9:58AM

Ocular Therapeutix Option Alert: Nov 19 $12 Calls Sweep (20) near the Ask: 396 @ $0.928 vs 22 OI; Earnings 11/4 After Close [est] Ref=$10.18

Benzinga - Sep 21, 2021, 1:05PM

Ocular Therapeutix Reports Monthly In-Market Unit Sales Of DEXTENZA Billable Inserts Of 6,924 In July And 9,321 In August

Benzinga - Sep 13, 2021, 6:48AM

JMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $33

Benzinga - Sep 9, 2021, 8:16AM

HC Wainwright & Co. Upgrades Ocular Therapeutix to Buy, Announces $17 Price Target

Benzinga - Aug 10, 2021, 6:27AM

Ocular Therapeutix Filing Shows Registration For $100M Common Stock Offering

Benzinga - Aug 9, 2021, 4:46PM

Ocular Therapeutix Q2 EPS $(0.25) Misses $(0.21) Estimate, Sales $11.72M Beat $11.60M Estimate

Benzinga - Aug 9, 2021, 4:23PM

Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases

Benzinga - Aug 6, 2021, 10:09AM

Ocular Therapeutix Announces Termination Of Collaboration With Regeneron To Develop A Sustained-Release Formulation Of Aflibercept For The Treatment Of Wet AMD And Other Serious Retinal Diseases

Benzinga - Aug 5, 2021, 4:23PM

Ocular Therapeutix Sponsored Study Titled 'Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration' Posted To ClinicalTrials.Gov Site

Benzinga - Aug 4, 2021, 8:43AM

Ocular Therapeutix Announces First Patient Dosed In US-Based Phase 1 Clinical Trial Of OTX-TKI For Treatment Of Wet Age-Related Macular Degeneration

Benzinga - Jul 29, 2021, 8:08AM

load more

Sector: Health Care.Industry: Pharmaceuticals

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, PTX-TP, and OTX-IVT.

Earnings

Q3 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-11-04
REV		(EXPECTED)2021-11-04

Q2 2021		Est.		Actual		Surprise
EPS		-0.210		-0.250		-0.0400
REV		11.600M		11.718M		118.000K

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Ocular Therapeutix Questions & Anwsers

Q

How do I buy Ocular Therapeutix (OCUL) stock?

A

You can purchase shares of Ocular Therapeutix (NASDAQ: OCUL) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Ocular Therapeutix's (OCUL) competitors?

A

Other companies in Ocular Therapeutix’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Theravance Biopharma (NASDAQ:TBPH), Sundial Growers (NASDAQ:SNDL), Aerie Pharmaceuticals (NASDAQ:AERI) and Phibro Animal Health (NASDAQ:PAHC).

Q

What is the target price for Ocular Therapeutix (OCUL) stock?

A

The latest price target for Ocular Therapeutix (NASDAQ: OCUL) was reported by Raymond James on October 18, 2021. The analyst firm set a price target for 29.00 expecting OCUL to rise to within 12 months (a possible 319.68% upside). 6 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Ocular Therapeutix (OCUL)?

A

The stock price for Ocular Therapeutix (NASDAQ: OCUL) is $6.91 last updated Fri Oct 22 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Q

Does Ocular Therapeutix (OCUL) pay a dividend?

A

There are no upcoming dividends for Ocular Therapeutix.

Q

When is Ocular Therapeutix (NASDAQ:OCUL) reporting earnings?

A

Ocular Therapeutix’s $Q3 earnings are confirmed for after-market on $November 4, 2021.

Q

Is Ocular Therapeutix (OCUL) going to split?

A

There is no upcoming split for Ocular Therapeutix.

Q

What sector and industry does Ocular Therapeutix (OCUL) operate in?

A

Ocular Therapeutix is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.